ES2181281T3 - Formulaciones liquidas de interferon beta. - Google Patents

Formulaciones liquidas de interferon beta.

Info

Publication number
ES2181281T3
ES2181281T3 ES98950074T ES98950074T ES2181281T3 ES 2181281 T3 ES2181281 T3 ES 2181281T3 ES 98950074 T ES98950074 T ES 98950074T ES 98950074 T ES98950074 T ES 98950074T ES 2181281 T3 ES2181281 T3 ES 2181281T3
Authority
ES
Spain
Prior art keywords
beta
liquid formulations
buffered
interfer
hsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950074T
Other languages
English (en)
Other versions
ES2181281T5 (es
Inventor
Michael Tschope
Thomas Siklosi
Peter Schroeder
Hans Hofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RENTSCHLER BIOTECH GmbH
Original Assignee
RENTSCHLER BIOTECH GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227392&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2181281(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by RENTSCHLER BIOTECH GmbH filed Critical RENTSCHLER BIOTECH GmbH
Application granted granted Critical
Publication of ES2181281T3 publication Critical patent/ES2181281T3/es
Publication of ES2181281T5 publication Critical patent/ES2181281T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Gyroscopes (AREA)

Abstract

Formulación líquida que contiene interferón humano como sustancia activa, un tampón para el ajuste de un valor pH de 5 a 8 y uno o varios aminoácidos y, después del almacenamiento durante 3 meses a 25ºC, presenta una estabilidad a largo plazo de la actividad biológica in vitro de al menos 80% de la actividad inicial, con la condición de que la formulación no contenga ningún aminoácido ácido, arginina ni glicina en una fracción en peso de 0,3 a 5%.
ES98950074T 1997-09-23 1998-09-23 Formulaciones liquidas de interferon beta. Expired - Lifetime ES2181281T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97116562 1997-09-23
EP97116562 1997-09-23

Publications (2)

Publication Number Publication Date
ES2181281T3 true ES2181281T3 (es) 2003-02-16
ES2181281T5 ES2181281T5 (es) 2008-04-16

Family

ID=8227392

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98950074T Expired - Lifetime ES2181281T5 (es) 1997-09-23 1998-09-23 Formulaciones liquidas de interferon beta.
ES02004883T Expired - Lifetime ES2223017T5 (es) 1997-09-23 1998-09-23 Formulaciones liquidas de un interferon beta.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02004883T Expired - Lifetime ES2223017T5 (es) 1997-09-23 1998-09-23 Formulaciones liquidas de un interferon beta.

Country Status (13)

Country Link
US (2) US6923956B1 (es)
EP (3) EP1426058A3 (es)
JP (1) JP4293497B2 (es)
KR (2) KR100711990B1 (es)
AT (2) ATE224726T1 (es)
AU (1) AU741300B2 (es)
CA (1) CA2304808C (es)
DE (2) DE59811910D1 (es)
DK (1) DK1017413T4 (es)
ES (2) ES2181281T5 (es)
IL (3) IL135186A0 (es)
PT (2) PT1017413E (es)
WO (1) WO1999015193A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6923956B1 (en) 1997-09-23 2005-08-02 Rentschler Biotechnologie Gmbh Liquid interferon-β formulations
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
US20050276823A1 (en) * 2002-07-12 2005-12-15 Cini John K Methods and compositions for preventing oxidative degradation of proteins
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE554792T1 (de) * 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
ZA200609412B (en) 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
US7731948B2 (en) * 2004-06-01 2010-06-08 Ares Trading S.A. Stabilized interferon liquid formulations
KR101191536B1 (ko) * 2004-06-01 2012-10-15 아레스 트레이딩 에스.에이. 안정화된 인터페론 액상 제제
BRPI0517697A (pt) * 2004-11-10 2008-10-14 Chiron Corp interferon-beta deamidado
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug
SI1917276T1 (en) * 2005-08-26 2018-05-31 Ares Trading S.A. PROCEDURE FOR PREPARATION OF GLYCOSYLATED INTERFERONE BETA
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP2234645B1 (en) 2007-12-20 2012-05-02 Merck Serono S.A. Peg-interferon-beta formulations
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
DE102008060960A1 (de) * 2008-12-06 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Optische Füllstandsmessung
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
BR112015009462A2 (pt) * 2012-10-26 2017-07-04 Lupin Atlantis Holdings Sa composição farmacêutica estável do tnfr:fc proteína de fusão
WO2014078627A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
KR860001471B1 (ko) 1980-04-03 1986-09-26 비오겐 엔. 브이 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
EP0082481B2 (en) † 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59181224A (ja) † 1983-03-29 1984-10-15 Sumitomo Chem Co Ltd 安定なインタ−フエロン製剤の製法
US4816440A (en) 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
EP0284249A1 (en) † 1987-03-13 1988-09-28 Interferon Sciences, Inc. Lyophilized lymphokine composition
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US4895716A (en) † 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
ATE110571T1 (de) * 1988-05-06 1994-09-15 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
JPH06247870A (ja) 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
CA2275890C (en) † 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations
US6923956B1 (en) † 1997-09-23 2005-08-02 Rentschler Biotechnologie Gmbh Liquid interferon-β formulations

Also Published As

Publication number Publication date
EP1017413B1 (de) 2002-09-25
KR100711990B1 (ko) 2007-05-02
KR100826621B1 (ko) 2008-05-02
EP1224940B1 (de) 2004-09-01
EP1017413B2 (de) 2007-11-07
KR20060088910A (ko) 2006-08-07
WO1999015193A1 (de) 1999-04-01
IL211048A (en) 2012-12-31
CA2304808A1 (en) 1999-04-01
ATE224726T1 (de) 2002-10-15
ES2181281T5 (es) 2008-04-16
ES2223017T3 (es) 2005-02-16
US8337826B2 (en) 2012-12-25
DE59805732D1 (de) 2002-10-31
IL135186A (en) 2012-12-31
PT1224940E (pt) 2005-01-31
EP1426058A2 (de) 2004-06-09
DE59811910D1 (de) 2004-10-07
EP1224940A8 (de) 2002-11-20
US20050186177A1 (en) 2005-08-25
EP1224940B2 (de) 2010-08-11
JP2001517635A (ja) 2001-10-09
JP4293497B2 (ja) 2009-07-08
AU741300B2 (en) 2001-11-29
PT1017413E (pt) 2003-02-28
US6923956B1 (en) 2005-08-02
CA2304808C (en) 2011-03-22
DK1017413T4 (da) 2008-03-25
KR20010015599A (ko) 2001-02-26
DK1017413T3 (da) 2003-02-03
ATE274917T1 (de) 2004-09-15
ES2223017T5 (es) 2010-10-15
AU9627698A (en) 1999-04-12
EP1017413A1 (de) 2000-07-12
EP1426058A3 (de) 2004-07-28
IL135186A0 (en) 2001-05-20
EP1224940A1 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
ES2181281T3 (es) Formulaciones liquidas de interferon beta.
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
DE3689870D1 (de) Formulierung für rekombinantes beta-Interferon, Verfahren zur Gewinnung und Stabilisierung des beta-Interferons und dessen Verwendung.
LU90806I2 (fr) Ovidrelle-choriogonadotropine alfa et ses d-riv-s pharmaceutiquement acceptables
DE69428040T2 (de) Orale darreichungsform
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
LV10178A (lv) Fiziologiski saderigu glabajot stabilu cilveka olbaltumvielu preparatu iegusanas panemiens
DE69329367D1 (de) Wachstumshormon-enthaltendeproteinformulierung
ES2107051T3 (es) Formulaciones de proteinas de liberacion sostenida.
IL84985A (en) Sialic acid derivatives with an active carbonyl group useful for extending biological half-life of physiological agents and as couplers for affinity chromatography
FR2805821B1 (fr) Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
ATE106743T1 (de) Fgf enthaltende stabilisierte zubereitungen.
ES8900018A1 (es) Procedimiento para la fabricacion de derivados aminoalcoholes peptidicos inhibidores de la renina y de las proteasas acidas
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
Sauder et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
Davies Secretory functions of mononuclear phagocytes: overview and methods for preparing conditioned supernatants
IT8820978A0 (it) Composizione erbicida conselettivita' aumentata e processo per la preparazione di entrambi i componenti ingredienti attivi in un solo stadio.
Newton Progress in Nitrogenase-Related Research
IT1233426B (it) Composizioni farmaceutiche per uso orale ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle
NZ509773A (en) Casein formulations for the delivery of bioactive constituents
IL101426A0 (en) Amino-coupled sialic acid derivatives with an active carbonyl group useful for extending biological half-life of physiological agents and as couplers for affinity chromatography